Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of prolgolimab plus pemetrexed and platinum versus placebo plus pemetrexed and platinum for first-line metastatic nonsquamous NSCLC
CTR20210732Phase 3Active
- Sponsor
- SPH-BIOCAD
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of prolgolimab in non-small cell lung cancer (NSCLC), sponsored by SPH-BIOCAD. Started Sep 2021; status: active.
02
Drugs
prolgolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210732.